![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SW Tam and LY Liu-Chen
The effect of beta-funaltrexamine (beta-FNA), an irreversible mu receptor blocker in isolated tissue bioassays, on mu, kappa and delta opioid receptor binding and the binding of beta-[3H]FNA were determined in guinea pig brain membranes. beta-FNA inhibited the binding of mu, kappa and delta opioid ligands to their receptors with Ki values of 2.2, 14 and 78 nM, respectively. Pretreatment of brain membranes with beta-FNA (less than 2 microM) followed by extensive washing inhibited mu binding and to a lesser degree delta binding, without changing kappa binding. The extent of the irreversible inhibition was dependent on the concentration of beta-FNA, and this inhibition on mu binding could be observed with as little as 1 nM beta-FNA. The irreversible inhibition of mu binding by beta-FNA pretreatment was due to a decrease in the number of binding sites with little change in Kd, and was more pronounced in the presence of increasing concentrations of NaCl. Specific binding of beta-[3H]FNA to opioid receptors was demonstrated. The rate of specific binding with 2 nM beta-[3H]FNA was rapid in the initial 10 min and did not reach maximum in 90 min. The dissociation of bound beta-[3H]FNA (5 nM added) by the addition of excess unlabeled naloxone reached maximum at 30 min with approximately 35% of specifically bound beta-[3H]FNA remaining. Mu opioids were most effective in preventing specific binding of beta-[3H]FNA when added before beta-[3H]FNA. Opioids added 1 hr after 2 nM beta-[3H]FNA could displace maximally only 70 to 75% of specific binding.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  J. H. Broadbear, T. L. Sumpter, T. F. Burke, S. M Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor Methocinnamox Is a Potent, Long-Lasting, and Selective Antagonist of Morphine-Mediated Antinociception in the Mouse: Comparison with Clocinnamox, beta -Funaltrexamine, and beta -Chlornaltrexamine J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 933 - 940. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Chen, J. Yin, J. K. d. Riel, R. L. DesJarlais, L. F. Raveglia, J. Zhu, and L.-Y. Liu-Chen Determination of the Amino Acid Residue Involved in [3H]beta -Funaltrexamine Covalent Binding in the Cloned RatµOpioid Receptor J. Biol. Chem., August 30, 1996; 271(35): 21422 - 21429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, J.-C. Xue, J. Zhu, Y.-W. Chen, S. Kunapuli, J. K. d. Riel, L. Yu, and L.-Y. Liu-Chen Characterization of Irreversible Binding of [IMAGE]-Funaltrexamine to the Cloned Rat µ Opioid Receptor J. Biol. Chem., July 28, 1995; 270(30): 17866 - 17870. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
